[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE345805T1 - Calciumtrifluoracetat mit zytotoxischer wirkung - Google Patents

Calciumtrifluoracetat mit zytotoxischer wirkung

Info

Publication number
ATE345805T1
ATE345805T1 AT02764607T AT02764607T ATE345805T1 AT E345805 T1 ATE345805 T1 AT E345805T1 AT 02764607 T AT02764607 T AT 02764607T AT 02764607 T AT02764607 T AT 02764607T AT E345805 T1 ATE345805 T1 AT E345805T1
Authority
AT
Austria
Prior art keywords
calcium
medicaments
trifluorocetate
cytotoxic effect
tumor
Prior art date
Application number
AT02764607T
Other languages
English (en)
Inventor
Alberto Bartorelli
Original Assignee
Bionest Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionest Ltd filed Critical Bionest Ltd
Application granted granted Critical
Publication of ATE345805T1 publication Critical patent/ATE345805T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02764607T 2001-07-12 2002-07-01 Calciumtrifluoracetat mit zytotoxischer wirkung ATE345805T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI001495A ITMI20011495A1 (it) 2001-07-12 2001-07-12 Sali di calcio ad attivita' citotossica

Publications (1)

Publication Number Publication Date
ATE345805T1 true ATE345805T1 (de) 2006-12-15

Family

ID=11448051

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02764607T ATE345805T1 (de) 2001-07-12 2002-07-01 Calciumtrifluoracetat mit zytotoxischer wirkung

Country Status (10)

Country Link
US (1) US7423063B2 (de)
EP (1) EP1423131B1 (de)
JP (1) JP4395368B2 (de)
AT (1) ATE345805T1 (de)
CA (1) CA2455710C (de)
DE (1) DE60216292T2 (de)
ES (1) ES2277620T3 (de)
IL (2) IL159770A0 (de)
IT (1) ITMI20011495A1 (de)
WO (1) WO2003006031A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040665A1 (it) * 2004-04-02 2004-07-02 Pharmaproducts Uk Ltd Sale di calcio per il trattamento della psoriasi e di dermatiti
ITMI20041279A1 (it) * 2004-06-24 2004-09-24 Pharmaproducts Uk Ltd Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico
ITMI20041822A1 (it) * 2004-09-24 2004-12-24 Pharmaproducts Uk Ltd "agente terapeutico utile per il trattamento di neoplasie plasmacellulari"
EP2796135A1 (de) 2013-04-22 2014-10-29 Polichem S.A. Verwendung von Trifluoressigsäure und Salzen davon zur Behandlung von Hypercholesterinämie
EP2845591A1 (de) 2013-09-04 2015-03-11 Polichem S.A. Verwendung von Trifluoressigsäure als keratolytischer Wirkstoff zur Behandlung hyperkeratotischer Hautläsionen
KR101683635B1 (ko) 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
SG11202006601VA (en) 2018-01-12 2020-08-28 Metimedi Pharmaceuticals Co Ltd Methods of treating chronic inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636564A (en) * 1984-11-13 1987-01-13 Board Of Trustees Of The University Of Alabama 5-cyanopyridine-2-diazohydroxide, basic salts and methods for production and use
US4880660A (en) * 1987-08-28 1989-11-14 Minnesota Mining And Manufacturing Company Method for priming hard tissue
US5250545A (en) * 1988-02-12 1993-10-05 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitor methods
UA32427C2 (uk) * 1993-10-15 2000-12-15 Елі Ліллі Енд Компані Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
US5593987A (en) * 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer

Also Published As

Publication number Publication date
US20040180956A1 (en) 2004-09-16
EP1423131B1 (de) 2006-11-22
CA2455710C (en) 2012-08-28
EP1423131A1 (de) 2004-06-02
US7423063B2 (en) 2008-09-09
WO2003006031A1 (en) 2003-01-23
IL159770A0 (en) 2004-06-20
ES2277620T3 (es) 2007-07-16
JP2004536120A (ja) 2004-12-02
DE60216292T2 (de) 2007-08-30
JP4395368B2 (ja) 2010-01-06
DE60216292D1 (de) 2007-01-04
ITMI20011495A0 (it) 2001-07-12
IL159770A (en) 2009-09-22
CA2455710A1 (en) 2003-01-23
ITMI20011495A1 (it) 2003-01-12

Similar Documents

Publication Publication Date Title
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
HRP20050436A2 (en) Quinolinyl-pyrrolopyrazoles
NO20032027L (no) Effektive antitumorbehandlinger
BR0213906A (pt) Métodos para a produção de um efeito anti-angiogênico e ou redutor da permeabilidade vascular em um animal de sangue quente, e para o tratamento de um câncer em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6474 ou um seu sal farmaceuticamente aceitável e um taxano
BR0313117A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável
MY164077A (en) Compositions and uses of et743 for treating cancer
BR0313116A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como humano, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável.
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
DE60116075D1 (de) Behandlung von tumoren mit photodynamischer therapie
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE330600T1 (de) Kombinationspräparat zur krebstherapie
ATE545423T1 (de) Mittel zur behandlung von lungenkrebs
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
ATE464051T1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
BRPI0407301A (pt) Uso de uma combinação, composição farmacêutica, kit, e, método para o tratamento de câncer em um animal de sangue quente tal como um ser humano
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
RU2002103977A (ru) Способ лечения острого гнойного пиелонефрита
DE60308403D1 (de) Kombinationstherapie mit gemzitabin und zd6126

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1423131

Country of ref document: EP

EEIH Change in the person of patent owner